Skip to content

McKesson MCK Oncology & Multispecialty — Goodwill acquired

Other segment segments

Prescription Technology Solutions
$39M
Medical-Surgical Solutions
$0
North American Pharmaceutical
$0

Similar metrics at other companies

Welltower logo
WELLOutpatient Medical — Goodwill acquired
$0
Boston Scientific logo
BSXMedSurg — Goodwill acquired
$274M
Solventum logo
SOLVMedSurg — Goodwill
$4.18B+13.9%
BrightSpring Health Services, Inc. logo
BTSGGoodwill
$2.53B+6.9%
Merck & Co. logo
MRKGoodwill
$21.58B-0.5%
Perrigo Company logo
PRGOSpecialty Care — Goodwill
$597.3M

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$98.45B+11.6%
Enterprise value$96.75B0.0%
P/E20.7×-7.2×
P/S0.2×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: McKesson’s 10-Q, filed February 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about McKesson's oncology & multispecialty — goodwill acquired.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is McKesson's oncology & multispecialty — goodwill acquired?
McKesson (MCK) reported oncology & multispecialty — goodwill acquired of $28M in Q4 2025.
What does oncology & multispecialty — goodwill acquired mean?
The premium paid over the fair value of net identifiable assets during an acquisition within the oncology and multispecialty segment. This reflects the company's investment in inorganic growth and the expected future synergies from these specific healthcare acquisitions.